Comparison of the efficacy of the tumour necrosis factor alpha blocking agents etanercept and infliximab in patients with active rheumatoid arthritis

被引：0
|
作者：
De Filippis, LG [1 ]
Caliri, A [1 ]
Scibilia, G [1 ]
Miceli, G [1 ]
Romano, C [1 ]
Sangari, D [1 ]
Bartolone, S [1 ]
Lo Gullo, R [1 ]
Bagnato, G [1 ]
机构：
[1] Univ G Martino, Policlin, Rheumatol Unit, Messina, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：411 / 411
页数：1
相关论文
共 50 条
  • [1] Improving outcomes in tumour necrosis factor α treatment:: comparison of the efficacy of the tumour necrosis factor α blocking agents etanercept and infliximab in patients with active rheumatoid arthritis
    De Filippis, L.
    Caliri, A.
    Anghelone, S.
    Scibilia, G.
    Lo Gullo, R.
    Bagnato, G.
    PANMINERVA MEDICA, 2006, 48 (02) : 129 - 135
  • [2] Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
    Hochberg, MC
    Tracy, JK
    Hawkins-Holt, M
    Flores, RH
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 13 - 16
  • [3] EFFICACY AND SAFETY OF LEFLUNOMIDE OR METHOTREXATE PLUS SUBCUTANEOUS TUMOUR NECROSIS FACTOR-ALPHA BLOCKING AGENTS IN RHEUMATOID ARTHRITIS
    Benucci, M.
    Saviola, G.
    Baiardi, P.
    Manfredi, M.
    Sarzi-Puttini, P.
    Atzeni, F.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2011, 24 (01) : 269 - 274
  • [4] Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis
    Flendrie, M
    Creemers, MCW
    Welsing, PMJ
    den Broeder, AA
    van Riel, PLCM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 30 - 33
  • [5] Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis
    Padyukov, L
    Lampa, J
    Heimbürger, M
    Ernestam, S
    Cederholm, T
    Lundkvist, I
    Andersson, P
    Hermansson, Y
    Harju, A
    Klareskog, L
    Bratt, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (06) : 526 - 529
  • [6] EFFICACY AND SAFETY OF TUMOUR NECROSIS FACTOR ALPHA INHIBITORS IN RHEUMATOID ARTHRITIS
    Baraza Cristina, Gomez
    Francisco Javier, Manero Ruiz
    Espasol Angela, Pecondon
    Mendoza Mercedes, Arenere
    Orbis Iciar, Casiamares
    Maria Jose, Rabanaque Hernandez
    ATENCION FARMACEUTICA, 2013, 15 (03): : 150 - 157
  • [7] The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
    Hansen, KE
    Hildebrand, JP
    Genovese, MC
    Cush, JJ
    Patel, S
    Cooley, DA
    Cohen, SB
    Gangnon, RE
    Schiff, MH
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (06) : 1098 - 1102
  • [8] The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients
    Berkhout, Lea C.
    l'Ami, Merel J.
    Krieckaert, Charlotte L. M.
    Vogelzang, Erik H.
    Kos, Dorien
    Nurmohamed, Michael T.
    Wolbink, Gerrit J.
    Rispens, Theo
    RHEUMATOLOGY, 2020, 59 (07) : 1703 - 1708
  • [9] Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
    Takeuchi, Tsutomu
    Miyasaka, Nobuyuki
    Tatsuki, Yoshihiko
    Yano, Toshiro
    Yoshinari, Toru
    Abe, Tohru
    Koike, Takao
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (07) : 1208 - 1215
  • [10] Effects of tumour necrosis factor alpha blockade on lipid profile in active rheumatoid arthritis
    Del Porto, F.
    Lagana, B.
    Nofroni, I.
    Tinti, F.
    Mitterhofer, A. P.
    D'Amelio, R.
    RHEUMATOLOGY, 2007, 46 (10) : 1626 - 1627
12345